UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs

UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best small-cap biotech stocks to buy according to analysts.

UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs

On November 6, 2025, UroGen Pharma Ltd. (NASDAQ:URGN) reported its Q3 2025 results, highlighting strong growth in demand alongside its steady commercial expansion. Furthermore, preliminary October figures indicated that demand revenue more than doubled compared to the previous three months. This growth reflects the increasing adoption of physicians amid operational delays. The company closed the quarter with $127.4 million in cash and marketable securities.

As the permanent billing code takes effect in early 2026, UroGen Pharma Ltd. (NASDAQ:URGN) anticipates a smoother process, despite product uptake potentially facing administrative lags of up to 60 days due to reimbursement and coding complexities. Furthermore, the company noted an expansion of its sales force to 82 representatives. With this expansion, the company strengthened physician outreach and patient access across major payers, with coverage accounting for over 95% of insured lives.

The quarter saw UroGen Pharma Ltd. (NASDAQ:URGN)’s net loss widen from $23.7 million in Q3 2024 to $33.3 million, driven by rising R&D expenses and delayed revenue recognition. Looking ahead, the company appears to be in a solid position, focusing on optimizing patient onboarding and accelerating reimbursement cycles, which is well supported by the growth in product demand noted in October. UroGen provided revenue guidance for only JELMYTO, expecting $94 million to $98 million in net revenues for the full year.

UroGen Pharma Ltd. (NASDAQ:URGN) focuses on developing and marketing specialty cancer treatments, delivering targeted, minimally invasive therapies.

While we acknowledge the potential of URGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than URGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.